Submission of Annual Report for FY 2024-25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kabra Drugs Limited has submitted its 36th Annual Report for FY 2024-25, with the AGM scheduled for 30 September 2025 in Indore. The company reported no revenue from operations, with only other income of Rs. 64.02 lakhs against total expenses of Rs. 172.53 lakhs, resulting in a loss after tax of Rs. 108.56 lakhs (EPS of negative Rs. 0.99), wider than the Rs. 73.61 lakh loss in FY 2023-24. No dividend has been recommended due to accumulated losses. The company raised funds through preferential allotments—56.9 lakh shares in July 2024 and 1.36 crore shares at a Rs. 6 premium in February 2025—taking paid-up capital to Rs. 23.71 crore. AGM business includes approving Rs. 14 lakh per annum remuneration to Executive Director Mr. K. N. Anand despite the losses, and appointing Mr. Tanuj Jain Susilkumar as Secretarial Auditor for a five-year term (FY 2025-26 to 2029-30).
Shareholders should note that the company recorded zero operating revenue and a deeper loss year-on-year, with a total of about Rs. 2 crore equity raised through preferential issues during the year to fund operations; the AGM will seek approval to pay director remuneration despite ongoing losses and to appoint a new secretarial auditor for the next five years.